Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Eur J Heart Fail. 2021 Jul;23(7):1191-1201. doi: 10.1002/ejhf.2163. Epub 2021 Apr 13.
Implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains incomplete. Non-cardiovascular hospitalization may present opportunities for GDMT optimization. We assessed the efficacy and durability of a virtual, multidisciplinary 'GDMT Team' on medical therapy prescription for HFrEF.
Consecutive hospitalizations in patients with HFrEF (ejection fraction ≤40%) were prospectively identified from 3 February to 1 March 2020 (usual care group) and 2 March to 28 August 2020 (intervention group). Patients with critical illness, de novo heart failure, and systolic blood pressure <90 mmHg in the preceeding 24 hs prior to enrollment were excluded. In the intervention group, a pharmacist-physician GDMT Team provided optimization suggestions to treating teams based on an evidence-based algorithm. The primary outcome was a GDMT optimization score, the sum of positive (+1 for new initiations or up-titrations) and negative therapeutic changes (-1 for discontinuations or down-titrations) at hospital discharge. Serious in-hospital safety events were assessed. Among 278 consecutive encounters with HFrEF, 118 met eligibility criteria; 29 (25%) received usual care and 89 (75%) received the GDMT Team intervention. Among usual care encounters, there were no changes in GDMT prescription during hospitalization. In the intervention group, β-blocker (72% to 88%; P = 0.01), angiotensin receptor-neprilysin inhibitor (6% to 17%; P = 0.03), mineralocorticoid receptor antagonist (16% to 29%; P = 0.05), and triple therapy (9% to 26%; P < 0.01) prescriptions increased during hospitalization. After adjustment for clinically relevant covariates, the GDMT Team was associated with an increase in GDMT optimization score (+0.58; 95% confidence interval +0.09 to +1.07; P = 0.02). There were no serious in-hospital adverse events.
Non-cardiovascular hospitalizations are a potentially safe and effective setting for GDMT optimization. A virtual GDMT Team was associated with improved heart failure therapeutic optimization. This implementation strategy warrants testing in a prospective randomized controlled trial.
射血分数降低的心力衰竭(HFrEF)患者的指南指导下的医学治疗(GDMT)实施仍不完整。非心血管住院可能为 GDMT 优化提供机会。我们评估了虚拟多学科“GDMT 团队”对 HFrEF 药物治疗处方的疗效和持久性。
连续住院的 HFrEF 患者(射血分数≤40%)于 2020 年 2 月 3 日至 3 月 1 日(常规护理组)和 2020 年 3 月 2 日至 8 月 28 日(干预组)前瞻性确定。排除患有危重病、新发心力衰竭和入院前 24 小时内收缩压<90mmHg 的患者。在干预组中,药剂师-医师 GDMT 团队根据循证算法为治疗团队提供优化建议。主要结局是出院时 GDMT 优化评分,即阳性(新起始或滴定增加+1)和阴性治疗变化(停药或滴定减少-1)的总和。评估了严重的院内安全事件。在 278 例连续的 HFrEF 就诊中,有 118 例符合入选标准;29 例(25%)接受常规护理,89 例(75%)接受 GDMT 团队干预。在常规护理就诊中,住院期间 GDMT 处方没有变化。在干预组中,β受体阻滞剂(72%至 88%;P=0.01)、血管紧张素受体-脑啡肽酶抑制剂(6%至 17%;P=0.03)、盐皮质激素受体拮抗剂(16%至 29%;P=0.05)和三联疗法(9%至 26%;P<0.01)的处方在住院期间增加。在校正了临床相关协变量后,GDMT 团队与 GDMT 优化评分的增加相关(+0.58;95%置信区间+0.09 至+1.07;P=0.02)。没有严重的院内不良事件。
非心血管住院可能是 GDMT 优化的一个安全有效的环境。虚拟 GDMT 团队与改善心力衰竭治疗优化相关。这种实施策略值得在前瞻性随机对照试验中进行测试。